Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases.
OBJECTIVE
Adenoid cystic carcinoma of the salivary gland (ACC-SG) is a slow-growing tumor that is refractory to most chemotherapeutic agents. Estrogen receptor (ER) antagonists provide a novel approach for recurrent disease.


METHODS
We report two cases of ACC-SC in which Tamoxifen/Toremifene were used.


RESULTS
Both patients obtained long-term stability of disease with no associated toxicity.


CONCLUSIONS
Given the relatively unsuccessful treatments for ACC-SC and the low toxicity of ER antagonists, such therapy should be considered in these patients for its potential disease-stabilizing effects.
Elkin
Adam D
AD
Department of Medicine, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.
Jacobs
Charlotte D
CD
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy* / Q000556:secondary; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012468:Salivary Gland Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013629:Tamoxifen / Q000627:therapeutic use*; D017312:Toremifene / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D017312:Toremifene